Tingting Fang

Tingting Fang

Auto-generated profile, based on publicly available information

Tingting Fang

Shandong Provincial Key Lab. of Animal Biotechnology and Disease Control and Prevention Lab of Aquatic Animal Nutrition & Environmental Health Shandong Agricultural University Taian City China

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 December 2020 in Medicine
Verified
Journal Article
Open access
TFTingting Fang
Tingting Fang
LLLanqin Liu
Lanqin Liu
WLWenjun Liu
Wenjun Liu
This is a study on the potential therapeutic targets and pharmacological mechanism of Tripterygium wilfordii (TW) in acute myeloid leukemia (AML) based on network pharmacology. Active components of TW were obtained by network pharmacology through oral bioavailability, drug-likeness filtration. Comparative analysis was used to investigate the overlapping genes between active ingredient's targets and AML treatment-related targets. Using STRING database to analyze interactions among overlapping genes. Both KEGG pathway analysis and Gene Ontology enrichment analysis were conducted in DAVID. These genes were analyzed for survival in OncoLnc database. We screened 53 active ingredients; the results of comparative analysis showed that 8 active ingredients had an effect on AML treatment. On the basis of the active ingredients and overlapping genes, we constructed the Drug-Compounds-Genes-Disease Network. Survival analysis of overlapping genes indicated that some targets possessed a significant influence on patients’ survival and prognosis. The enrichment analysis showed that the main pathways of targets were Toll-like receptor signaling pathway, NF-kappa B signaling pathway, and HIF-1 signaling pathway. This study, using a network pharmacologic approach, provides another strategy that can help us to understand the mechanisms by which TW treats AML comprehensively.

21 March 2021 in Aquaculture Research
Verified
Journal Article
Open access
PDF file
DGDongyan Guan
Dongyan Guan
HSHuiwen Sun
Huiwen Sun
JWJiting Wang
Jiting Wang
ZWZhen Wang
Zhen Wang
YLYang Li
Yang Li
TFTingting Fang
Tingting Fang
This study aimed to investigate the effects of rosiglitazone on glucose metabolism of GIFT tilapia based on the PI3K/Akt signalling pathway. The experiment was divided into five groups: normal starch group (32%, LC), high starch group (53%, HC), HC + rosiglitazone group 1 (10 mg/kg, R1), HC + rosiglitazone group 2 (20 mg/kg, R2) and HC + rosiglitazone group 3 (30 mg/kg, R3). The results showed that a high starch diet added with 10–20 mg/kg rosiglitazone had a better specific growth rate and protein efficiency that was beneficial for the growth of the tilapia. With an increase in the rosiglitazone concentration, the contents of serum glucose, insulin and hepatic glycogen in the R1, R2 and R3 groups decreased gradually. Meanwhile, the muscle glycogen content in the R1, R2 and R3 groups increased gradually. The mRNA expression of the IRS‐1, PI3K, GLUT‐4 and Akt proteins in the R1, R2 and R3 groups was significantly higher than that in the HC group (p < 0.05). Compared with the HC group, the expression of the GSK‐3 mRNA in the R1, R2 and R3 groups was significantly reduced (p < 0.05). The protein expression of p‐GSK‐3β (phosphorylated GSK‐3β) in the R1 and R2 groups was significantly higher than that in the HC group (p < 0.05). In conclusion, a high starch diet supplemented with rosiglitazone can improve growth, enhanced the serum biochemical indices and increase the muscle glycogen content in the GIFT tilapia. It benefits in upregulating the IRS‐1, PI3K and GLUT‐4 mRNA in the skeletal muscle and promotes glucose uptake. Meanwhile, the phosphorylation of Akt and GSK‐3β increased significantly and resulted in the inactivation of GSK‐3β and alleviation of insulin resistance. Under these experimental conditions, the optimal dosage of rosiglitazone on tilapia was 10–20 mg/kg diet.